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Abstract
Background: 25-hydroxycholesterol (25-OHC) is a product of oxidation of dietary cholesterol present in human
plasma. 25-OHC and other oxidized forms of cholesterol are implicated in modulating inflammatory responses
involved in development of atherosclerosis and colon carcinogenesis.
Methods: Primary lymphatic, venous and arterial endothelial cells isolated from bovine mesentery (bmLEC, bmVEC,
bmAEC) were treated with 25-OHC and tested for several different cellular parameters.
Results: We found 25-OHC to be a potent inducer of cyclooxygenase-2 (Cox-2, prostaglandin G-H synthase-2)
expression in bovine mesenteric lymphatic, venous, and arterial endothelial cells. The induction of Cox-2 expression
in endothelial cells by 25-OHC led to an initial increase in cellular proliferation that was inhibited by the Cox-2
selective inhibitor celecoxib (Celebrex). Prolonged exposure to 25-OHC was cytotoxic. Furthermore, endothelial cells
induced to express Cox-2 by 25-OHC were more sensitive to the effects of the Cox-2 selective inhibitor celecoxib
(Celebrex). These results suggest that some effects of 25-OHC on cells may be dependent on Cox-2 enzymatic
activity.
Conclusions: Cox-2 dependent elevating effects of 25-OHC on endothelial cell proliferation was transient.
Prolonged exposure to 25-OHC caused cell death and enhanced celecoxib-induced cell death in a cell-type
dependent manner. The lack of uniform response by the three endothelial cell types examined suggests that our
model system of primary cultures of bmLECs, bmVECs, and bmAECs may aid the evaluation of celecoxib in
inhibiting proliferation of different types of tumour-associated endothelial cells.
Background
The enzyme cholesterol-25-hydroxylase (CH25H)
converts dietary cholesterol to 25-hydroxycholesterol
(25-OHC, cholest-5-ene-3b,2 5 - d i o l )i nav a r i e t yo ft i s -
sues including heart, lungs, kidney [1,2], and intestinal
epithelium [3]. As reviewed by Javitt, 25-OHC only
plays a minor role (approximately 5%) in bile acid synth-
esis in the liver and may play a more active role as a
ligand in the regulation of cholesterol synthesis and
transport [4]. Indeed, 25-OHC has been detected in
blood plasma [5] suggesting that it may have system-
wide effects in the body, although the biochemical func-
tion of 25-OHC has not been fully elucidated.
Some observations of the effects of 25-OHC include:
inhibition of 3-hydroxy-3-methyhydroxy-CoA (HMG-
CoA) reductase activity correlating with reduction in
mouse cultured fetal liver cell growth [6]; and inhibition
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[7]. HMG-CoA reductase and SREBPs are key players in
the synthesis of cholesterol and other isoprenoids in the
cell–HMG-CoA catalyses the rate-determining step and
SREBPs are transcription factors promoting the expres-
sion of genes involved in the process [8]. Thus, 25-OHC
is thought to attenuate cholesterol and steroid lipid bio-
synthesis, down-regulation of which is potentially linked
to observations that 25-OHC exposure causes cell-cycle
arrest and inhibits growth in immortalized and trans-
formed A31 mouse embryonic cells [9], and human pri-
mary prostate stromal cells in culture [10].
Potentially unrelated to the role of 25-OHC in regu-
lating cholesterol and isoprenoid synthesis are observa-
tions that 25-OHC induces apoptosis in the human
acute lymphoblastic leukemia cell line, CEM, by sup-
pression of c-myc expression [11,12], in mouse macro-
phage-like P388-D1 cells by suppression of the
cysteine protease, CPP32 [13], and in hamster ovarian
CHO-K1 cells by caspase activation [14]. Likewise, the
induction of cyclooxygenase-2 (Cox-2, prostaglandin
G-H synthase-2) expression in cultured bovine coron-
ary artery endothelial cells (ECs) does not depend on
the activity of Cytochrome P450 (CYP), which are
enzymes essential for cholesterol and isoprenoid bio-
synthesis [15]. Similar observations were noted in rab-
bit pulmonary arterial ECs and smooth muscle cells
(SMCs) exposed to 25-OHC. Treatment with 25-OHC
resulted in increased synthesis of eicosanoid products
of the arachidonic acid oxidation pathway partly cata-
lyzed by Cox-1 and -2 enzymes [16]. These observa-
tions contribute to the idea that 25-OHC play many
roles in cell biology that are only beginning to be
elucidated.
Whereas 25-OHC treatment leads to induction of
Cox-2 expression [15,16], treatment of cells with selec-
tive inhibitors to Cox-2 has been shown to induce cell
death in endothelial progenitor cells (EPCs) [17], and to
induce cell-cycle arrest in ECs [18]. The latter observa-
tions would suggest that 25-OHC treatment should pro-
mote Cox-2 expression and thereby should contribute
to cellular proliferation. However, studies such as by
Larsson and colleagues [9] and Wang and colleagues
suggest the opposite outcome [10].
In order to understand effects of 25-OHC on cells, we
exposed cultured primary bovine lymphatic and blood
ECs (bmECs), that do not normally express Cox-2, to
25-OHC. We found 25-OHC to induce Cox-2 expres-
sion in primary cultured bovine mesenteric lymphatic,
venous, and arterial ECs (bmLECs, bmVECs, bmAECs),
correlating with an initial increase in cell count. Expo-
sure of 25-OHC treated bmECs to the Cox-2-selective
inhibitor celecoxib (Celebrex) inhibited the observed
short burst of increase in cell count. We found bmECs
to be able to tolerate short exposures to low levels of
25-OHC. However, prolonged exposure to 25-OHC
resulted in cell death, which was more pronounced in
bmECs treated with celecoxib. These results suggest
some effects of 25-OHC may be dependent upon Cox-2
enzyme activity in ECs.
Methods
Cell Culture and 25-OHC Treatment
Primary bmLECs, bmVECs, and bmAECs were from
frozen stocks of bmECs previously isolated and
described by Nguyen and colleagues [19]. Human color-
ectal carcinoma cell line HCT-116 was obtained from
ATCC (American Type Culture Collection) and ECCC
and grown according to provided instructions. BmECs
were grown in standard tissue culture conditions in Dul-
becco’s Modified Eagle’s Medium (DMEM, Sigma
Aldrich) supplemented with 10% fetal bovine serum
(FBS, Sigma Aldrich). For all experiments involving
treatment with 25-OHC and/or celecoxib, dialyzed FBS
(Gibco). 5 μM Celecoxib was used unless otherwise
stated.
In all relevant experiments, the concentration of
25-OHC (dissolved in ethanol (EtOH), Sigma Aldrich)
w a sk e p tc o n s t a n ta t2 5μM as previously described by
Wohlfiel and Campbell [15] to be effective for induction
of Cox-2 expression. Wherever indicated, short exposure
of cells to 25-OHC means at most 24 hours, and pro-
longed exposure means at least 48 hours.
Detection of transcripts by RT-PCR
Total RNA was prepared from bmECs using Tri-Reagent
(Sigma Aldrich) according to manufacturer’s instructions.
cDNA was synthesized from 1 μgo ft o t a lR N Aw i t hT h e r -
moscript Reverse Transcriptase (Invitrogen) according to
manufacturer’s instructions. PCR was performed with Taq
polymerase (Qiagen) with primer sequences: Cox1 (for-
ward primer 5’-CTGTTGTTACTATCCATGCC-3’,
reverse primer 5’- CTGGAAAAGCTGCTCATCGC-3’),
Cox2 (forward primer 5’-GAGAAAACTGCTCAACA
CCG-3’, reverse primer 5’-GCATACTCTGTTGTGT
TCCC-3’), GAPDH (forward primer 5’-ACC ACA GTC
CAT GCC ATC AC-3’, reverse primer 5’-TCC ACC ACC
CTG TTG CTG TA-3’).
Viable Cell Counting
Cell counts were done using a hemocytometer. Cells
were stained with 0.08% Trypan Blue (Gibco) after tryp-
sin (Gibco) treatment. Eight μL of the cell suspension
was loaded into each side of the haemocytometer. Four
squares with similar cell distribution were counted. Blue
(non-viable) cells were excluded from tally. All experi-
ments were done in at least duplicates and repeated at
least twice.
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Cells were incubated with 25 μM 25-OHC and/or cele-
coxib at various concentrations for at least 60 hours
before harvesting. Cell death was quantified using the
Cell Death Dectection ELISA-Plus kit (Roche) according
to manufacturer’s instructions. Amount of coloured
immobilized antibodies-histone complexes was deter-
mined by spectrophotometric absorbance reading at 405
nm with wavelength correction set at 509 nm.
Statistical Analysis
Hypothesis testing by appropriate statistical tests was
done on all sets of data. P-values were calculated using
paired or unpaired, 1 or 2-tailed, student t-test or
ANOVA when appropriate, with the confidence interval
set at 95% (a = 0.05).
Results
25-OHC induces Cox-2 expression
As previously described by Wohlfeil and Campbell
[15,16], 25-OHC stimulates expression of Cox-2 in cul-
tured ECs. Wohlfeil and Campbell exposed bovine cor-
onary arterial cells to a concentration of 10 μg/mL
(25 μM) of 25-OHC for 48 hours. To determine
whether 25-OHC similarly induces Cox-2 expression
our bmLECs, bmVECs, and bmAECs, we treated ECs
with 25 μM added directly to culture media and left
overnight. By RT-PCR, bmLECs and bmAECs expressed
Cox-2 in the presence of 25-OHC but not in ethanol
(EtOH) vehicle alone. Cox-1, however, was constitutively
expressed in all three cell types (Figure 1A). Interest-
ingly, basal level of Cox-2 was high in bmVECs but not
in bmAECs or bmLECs. Cox-2 levels increased signifi-
cantly upon treatment of bmVECs with 25-OHC. Thus,
these results corroborate those reported by Wohlfeil and
Campbell [15,16].
Further corroborating results reported by Wohlfeil
and Campbell [15], who found 25-OHC to cause cul-
tured rabbit pulmonary arterial ECs and SMCs to take
on an elongated morphology, we also found changes in
morphology of our cultured bmECs. BmECs lost the
typical endothelial cobble-stoned morphology and
became elongated, forming partial swirls in the presence
of 25-OHC (Figure 1B).
Short 25-OHC exposure promotes proliferation
In addition to the changed morphology, we observed
that plates of cells treated with 25-OHC for 24 hours or
less appeared to be more tightly packed with cells than
those treated with ethanol vehicle alone. We also
observed some ECs loosely attached to and growing out-
side the monolayer (Figure 1b). Without 25-OHC treat-
ment, all three bmECs formed a monolayer in culture
with flat cells touching at all sides without squeezing
tightly together. This observation led us to hypothesize
t h a tp e r h a p st h e r ew a sa ni n c r e a s ei nt h en u m b e ro f
cells packed in the monolayer. Indeed, we found this to
be the case when we counted the cells after 24 hours of
growing cells in 25-OHC (Figure 2a). Interestingly,
the fold difference in the number of viable cells from
seeded cells (taken as 1 in figure 2a) seemed most pro-
n o u n c e di nb m L E C sc o m p a r e dt ob m V E C sa n d
bmAECs (Figure 2a).
To determine whether the increase in cell count was
dependent on Cox-2 enzyme activity, we treated cells
with the selective Cox-2 inhibitor celecoxib (Celebrex)
after 25-OHC exposure. When cells were treated with
25-OHC in the presence of celecoxib for 12 hours, cell
counts were the same as vehicle alone (Figure 2b). Parti-
cularly noteworthy was the count of bmVECs treated
with celecoxib: the number of viable bmVECs dropped
below the count of vehicle treated bmVECs (Figure 2b).
bmVECs seemed to be more sensitive to celecoxib in
culture media than bmAECs or bmLECs. This observa-
tion is in agreement with PCR results shown in figure
1a, where a high basal level of Cox-2 transcript was
Figure 1 Expression of Cox2 in mesenteric ECs. A/ 25-OHC
exposure induced Cox-2 expression in bmECs. ECs were treated
with 25 μM of 25-OHC added directly to culture media and left
overnight before mRNA harvest and RT-PCR. BmLECs and bmAECs
expressed Cox-2 in the presence of 25-OHC but not in EtOH vehicle
alone. Cox-1, however, was constitutively expressed in all three cell
types. Basal level of Cox-2 was high in bmVECs but not in bmAECs
or bmLECs. Cox-2 levels increased significantly upon treatment of
bmVECs with 25-OHC. B/ 25-OHC exposure changed morphology
cultured bmECs. ECs lost the typical endothelial cobble-stoned
morphology and became elongated, forming partial swirls in the
presence of 25-OHC but not in vehicle control.
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bmAECs or bmLECs; Cox-2 enzyme activity may play a
role in the growth of bmVECs in culture.
To determine whether proliferative effects of 25-OHC
on cells was restricted ECs, we subjected the human col-
orectal carcinoma cells HCT-116 to the same treatments
as the bmECs (Figure 2b). HCT-116 has previously been
shown to be Cox-2 deficient by Molina and colleagues
[20]. We found treatment of HCT-116 with 25-OHC
increased viable cell count and the increase to be
reversed by celecoxib as observed in bmECs (Figure 2b).
Therefore the proliferative effects of 25-OHC on cells
was not restricted to primary ECs but also applicable to
colorectal carcinoma cells in culture.
Figure 2 25-OHC promotes endothelial cell proliferation. A/ Short exposure to 25-OHC promoted EC proliferation. Viable cells that excluded
trypan blue were counted after 24 hours of growing cells in 25-OHC. Fold difference in the number of viable cells from seeded cells (taken as
1) was most pronounced in bmLECs compared to bmVECs and bmAECs. Mean of fold differences between treated and untreated bmAEC,
bmVEC, and bmLEC from three trials analysed by t-test yielded p-values of 0.021, 0.016, and 0.0036 respectively (n = 3). B/ Temporary boost in
EC proliferation due to 25-OHC exposure for 12 hours was dependent on Cox-2 activity. ECs were treated with the selective Cox-2 inhibitor
celecoxib for 12 hours after 25-OHC exposure. Celecoxib (5 μM) reversed the small increase in cell number of viable cells due to 25-OHC. The
number of viable bmVECs treated with celecoxib alone dropped below the number of viable vehicle-treated bmVECs. Proliferative effects of
25-OHC also applied to human colorectal carcinoma cells HCT-116. HCT-116 has previously shown to be Cox-2 deficient. For each cell type,
mean of fold differences between treatments from three trials analysed by ANOVA generated p-values ≤ 0.001 (n = 3). For each treatment with
celecoxib, 25-OHC, and both together, the mean fold differences between each cell type analysed by ANOVA generated p-values of 0.084, 0.011,
and 0.00038, respectively (n = 3).
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cell death
Although 25-OHC gave bmECs a boost in cellular pro-
liferation, primary bmECs did not lose contact inhibi-
tion. When ECs reached confluency after seeding, they
stopped growing even in the presence of 25-OHC.
Whether cells were confluent or still proliferating, we
observed that continued exposure to 25-OHC past 60
hours caused the cells to undergo cell death (Figure 3).
The level of cell death was measured at 72 hours by an
ELISA assay quantifying DNA fragmentation. BmAECs
were significantly more susceptible to cell death induced
by prolonged 25-OHC exposure than either bmVECs or
bmLECs. Furthermore, we were not able to rescue the
cells by inhibiting Cox-2 activity with 5 μMc e l e c o x i b
(Figure 3). This result suggests that cell death induced
by prolonged 25-OHC exposure was not dependent on
Cox-2 enzyme activity.
48 hour exposure to 25-OHC sensitizes cells with
undetectable basal levels of Cox-2 to effects of Celecoxib
Low doses of celecoxib (5-10 μM) have been shown to
induce G2/M cell cycle arrest through inhibition of
Cox-2 dependent prostaglandin E2 production [21]. In
order to compare the effects of celecoxib on cells with
undetectable basal levels of Cox-2 and cells induced to
express detectable levels of Cox-2, we performed cell
counts with trypan blue after growing cells for a period
of 48 hours in the presence of low doses of celecoxib.
We chose 48 hours because exposure of bmECs to
25-OHC over this period of time was not long enough
to result in toxic effects leading to massive cell death as
measured in Figure 3. Furthermore the initial growth
advantage conferred on cells by 25-OHC induction of
Cox-2 shown in Figure 1 was no longer detectable after
48 hours due to contact inhibition. Low dose celecoxib
caused the same reduction in viable bmLEC cell num-
b e r sw h e t h e ro rn o t2 5 - O H Cw a sp r e s e n t( F i g u r e4 a ) .
Unlike bmLECs, viable numbers of bmVECs not treated
with 25-OHC did not change as a result of treatment
with celecoxib until the concentration was above 5 μM
(Figure 4a). Unlike either bmVECs or bmLECs, even
5 μM of celecoxib reduced viable bmAEC cell counts,
which was reduced to a greater extent in the presence
of 25-OHC (Figure 4b). Treatment of bmAECs with
50 μM of celecoxib in the presence of 25-OHC caused
massive cell death reducing viable cell numbers to
below one-fifth of vehicle control. These results indicate
that each bmEC type exhibited different levels of sensi-
tivity to celecoxib with or without 25-OHC treatment.
To determine whether low doses of celecoxib also
increased reduction in viable cell counts of colorectal
carcinoma cells with undetectable basal Cox-2 expres-
sion, we performed the same experiment on colorectal
carcinoma cells HCT-116 previously shown to be Cox-2
deficient [20]. Unlike ECs, in the absence of 25-OHC,
viable HCT-116 cell numbers did not differ from vehicle
control even at 10 μM of celecoxib (Figure 4c). In the
presence of 25-OHC, HCT-116 viable cell numbers
reduced as celecoxib concentrations increased from
5 μMt o1 5μM (Figure 4c). These results indicate that
increased sensitivity to effects of celebrex as a result of
25-OHC exposure was not restricted to primary ECs
with undetectable basal levels of Cox-2 but also applic-
able to Cox-2-deficient colorectal carcinoma cells in
culture.
Discussion
We set out in this study to elucidate the effects of
25-OHC on mammalian cells and to determine
whether those effects are dependent on Cox-2. We
found as previously reported by Wohlfeil and Camp-
bell [15,16] that 25-OHC induces Cox-2 expression.
W ef o u n dt h a ts h o r te x p o s u r et o2 5 - O H Ct oi n d u c e
Cox-2 led to a temporary increase in viable cell num-
bers that was reversed by the Cox-2 inhibitor cele-
coxib. Low dose of celecoxib used (5 μM) ensured that
non-specific binding of celecoxib to other targets was
minimized–celecoxib is selective for Cox-2 at 5 μM,
below previously reported IC50 value of 15 μMf o rc e l -
ecoxib binding to Cox-1 (reviewed in [22]). Contrast-
ingly, the addition of celecoxib did not prevent cell
death following prolonged exposure to 25-OHC. These
results suggest that not all effects of 25-OHC on cells
were dependent on Cox-2 activity.
Figure 3 Long-term exposure to 25-OHC is toxic to ECs.
Exposure to 25-OHC past 60 hours caused the cells to undergo cell
death. Levels of EC death due to 25-OHC was measured at 72 hours
by ELISA assay quantifying DNA fragmentation. BmAECs were
significantly more susceptible to cell death induced by prolonged
25-OHC exposure than either bmVECs or bmLECs. Celecoxib at 5
μM did not reverse the cell death.
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table model cells for studies involving Cox-2 inhibitors
intended for human use. For example, Jung et al (2007)
used bovine aortic endothelial cells to demonstrate anti-
cancer properties of the Cox-2 inhibitor enoic acanthoic
acid [23]. For another example, Toker et al (2008)
demonstrated the relaxant effects of celecoxib on bovine
ciliary muscle [24]. Most significantly, Myers et al
(2010) demonstrated that bovine cells respond to non-
steroidal anti-inflammatory drugs (NSAIDs) intended
for human use similarly to other mammalian cells in
suppressing Cox-2 activity [25]. Bovine ECs are there-
fore highly suitable cell models for studies such as
described herein.
25-OHC is detected in human plasma at concentra-
tions ranges of 0 to 11 ng/mL [5], however, cultured
testicular macrophages have been shown to be capable
of producing high levels of 25-OHC comparable to the
quantity chosen in the present study (10 μg/mL) [26].
Nes et al (2000) reported cultured testicular macro-
phages were capable of producing 10 fg 25-OHC per
cell per hour [26]. Therefore media concentration of 25-
OHC can reach 10 μg/mL in approximately 4 days
assuming 50 million cells grown in 5 mL of media.
Furthermore, 10 μg/mL was shown by other members
of the same laboratory to be ineffective in causing cyto-
toxicity of Leydig cells, in which 25-OHC is metabolized
to form testosterone [27]. Only when Lukyanenko et al
(2001) used a concentration of 100 μg/mL over an expo-
sure period of 2 days did they observe toxicity to 50% of
Leydig cells [27]. To a lesser extent, the bovine ECs in
the present study were observed to be resistant to 25-
OHC cytotoxic effects at 10 μg/mL over an exposure
period of 1 day.
Previously, 25-OHC treatment was shown to increase
cell death, increase prostacyclin production (suggestive
of cyclooxygenase activity induction), and decrease pro-
liferation when compared to cholesterol treatment [28].
The cytotoxicity of 25-OHC on cultured human umbili-
cal arterial ECs was demonstrated by Kawamura and
Kummerow to be both concentration and time depen-
dent [28]. We have performed a similar examination of
25-OHC cytotoxicity on arterial as well as venous and
lymphatic ECs and found that not all EC types were
equally affected by 25-OHC exposure and/or celecoxib
treatment. BmAECs had the highest level of cell death
upon 25-OHC exposure (Figure 3). The effect of cele-
coxib on bmLECs did not seem to be dependent on 25-
OHC exposure (Figure 4a). Furthermore, cells with
undetectable levels of endogenous basal Cox-2 like
bmAECs and HCT-116 were further sensitized to cele-
coxib if they were previously exposed to 25-OHC (Fig-
ure 4b and 4c). Our results seem to suggest that effects
of 25-OHC may be cell-type dependent in addition to
Figure 4 48 hour exposure to 25-OHC sensitized Cox-2-negative
cells to effects of Celecoxib. A/ Celecoxib concentrations of 5 and
10 μM caused the same reduction in viable cell numbers of bmLECs
whether or not 25-OHC was present. Unlike bmLECs, viable numbers
of bmVECs not treated with 25-OHC did not change as a result of
treatment with celecoxib until the concentration was above 5 μM.
Mean of fold differences between EtOH-treated (vehicle, 25-OHC
untreated) bmLECs and bmVECs in the presence of 5 μM celecoxib
analysed by t-test generated p-value of 0.0005 (n = 4). B/ Unlike
either bmVECs or bmLECs, even 5 μM of celecoxib statistically
significantly reduced viable bmAEC cell counts slightly (p = 0.012, n =
4). Cell count was reduced to a greater extent in the presence of 25-
OHC. Mean fold differences between 25-OHC treated and 25-OHC
untreated bmAECs at 10 μM analysed by t-test generated p-value of
0.0004 (n = 4). C/ Low doses of celecoxib also increased reduction in
viable cell counts of colorectal carcinoma cells HCT-116 (previously
shown to be Cox-2 deficient) in the presence of 25-OHC. Unlike ECs,
viable HCT-116 cell numbers did not differ from vehicle control in the
absence of 25-OHC. Mean fold difference between cell counts of
HCT-116 treated and not treated with 25-OHC analysed by t-test
generated p-value of 0.029 at 5 μM celecoxib, and a p-value of
0.0006 at 15 μM (n = 3).
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sion by the cell.
Our results in Figure 1a corroborate work by others’
work establishing 25-OHC as an inducer of Cox-2
expression in ECs [15,16]. The fact that during inflam-
mation, Cox-2 expression in ECs is induced by cytokines
such as interleukin-1b (IL-1b)[ 2 9 ]r e l e a s e db ym a c r o -
phages, suggests that 25-OHC may be pro-inflammatory.
However, evidence exists indicating that 25-OHC may
be anti-inflammatory. This evidence comes from studies
of the Liver X Receptor (LXR), for which 25-OHC is an
agonistic ligand [30]. For example, synthetic LXR ago-
nists have been shown to inhibit IL-1b-induced produc-
tion of Prostaglandin E2 (PGE2), as well as Cox-2 in
osteoarthritic cartilage and in the synovial sarcoma cell
line SW982 [31]. For another example, LXR agonists
such as GW3965 inhibited expression of pro-inflamma-
tory mediators such as nitric oxide (NO) synthase,
Cox-2, and IL-6 in macrophages [32]. Although LXRs
are also expressed by ECs [33], Morello et al (2009)
established that pro-inflammatory effects of 25-OHC in
ECs are not dependent on LXRs [33]. Altogether these
studies indicate that 25-OHC may act as an anti-inflam-
matory agent in an LXR-dependent manner in certain
tissues and a pro-inflammat o r ya g e n ti na nL X R - i n d e -
pendent manner in other tissues, most notably ECs.
Indirectly, 25-OHC has been shown to induce
immune cells such as macrophages to express and
secrete interleukin-1b (IL-1b) [34], which induces Cox-2
expression in ECs [29] as well as in colon cancer cells
[35]. Macrophages and other immune cells are fre-
quently recruited to the site of tumourigenesis by factors
secreted by colon cancer cells [36]. Macrophages at the
site of tumourigenesis have been shown to activate
colon cancer cells by increasing their proliferation and
metastasis potential. Activated colon cancer cells in turn
stimulate blood ECs to undergo angiogenesis [37].
Moreover, 25-OHC in combination with IL-1b has been
shown to stimulate human colon carcinoma cells (Caco-
2) to produce IL-8 [38], which in turn is a promoter of
angiogenesis by stimulating endothelial cells prolifera-
tion, survival, migration, and MMP-2 production
[39,40]. Taken together, these results may suggest that
25-OHC at concentrations that are not cytotoxic may
participate in colon tumourigenesis with or without
Cox-2 involvement, although 25-OHC may cooperate
with some tumourigenic effects of Cox-2.
Since 25-OHC is an LXR activating ligand, and since
LXR has recently been suggested to inhibit proliferation
of breast cancer [41], it logically follows that 25-OHC
should perhaps be considered to be anti-tumourigenic.
However we suggested in the previous paragraph that
2 5 - O H Cm a yb ep r o - t u m o u r i g e n i cw h e ni ti sn o tc y t o -
toxic. Indeed, we observed that short-term exposure to
25-OHC stimulated EC proliferation, which could be
reversed by celecoxib (Figure 2). The apparent conflict
can be resolved when the contexts in which effects of
25-OHC on cells are considered. Results by Morello et
al (2009) using human umbilical venous endothelial
cells led the investigators to suggest that, at least in EC,
25-OHC was not as potent as other oxysterols such as
22-OHC or 24,25-OHC in activating LXR [33]. The sug-
gestion by these same investigators that perhaps more
prolonged exposure of cells to 25-OHC would lead to
more dramatic LXR-dependent effects was partly corro-
borated by our results indicating more prolonged expo-
sure of ECs to 25-OHC was required to cause
cytotoxicity (Figure 3). All together, these findings sug-
gest that not all effects of 25-OHC on cells are LXR-
dependent and mechanistically linked to the induction
of Cox-2 and thereby PGE2 production. Thus, 25-OHC
may still be considered a potential cytotoxic agent with
anti-cancer properties despite certain pro-inflammatory
characteristics such as the induction of Cox-2
expression.
In health, Cox-2 is normally not constitutively detect-
able in vascular endothelial cells and epithelial cells of
the gastrointestinal tract and is more commonly
detected in parts of the brain, kidney, pancreatic islet,
ovary and in uterine cells (reviewed in [42]). Cox-2
expression is induced in the event of injury by tissues
requiring damage repair and at sites of inflammation
(reviewed in [42]). In colon cancer, Cox-2 has been
f o u n dt ob ea b n o r m a l l yo v e r - e x p r e s s e di na b o u t9 0 %o f
colorectal adenocarcinomas and in 40-90% of colorectal
adenomas (reviewed in [43]). The abnormal over-expres-
sion of Cox-2 is not only found in tumour cells but also
in almost every cell type in the surrounding tumour
including fibroblasts, myofibroblasts, mononuclear
inflammatory cells, and most importantly, endothelial
cells (reviewed in [43]). Expression of Cox-2 in ECs sur-
rounding colorectal tumours has been shown to pro-
mote angiogenesis and lymphangiogenesis by
mechanisms dependent on PGE2 production. Products
of the enzymatic pathway perform such tasks as promo-
tion of EC proliferation, survival, increasing EC motility
towards the tumour, and up-regulation of VEGF-C
levels [44]. Expression of Cox-2 in ECs can also pro-
mote tumourigenesis by mechanisms independent of
PGE2 production such as activation of carcinogens [45]
and reduction in arachidonic levels [46]. These tumouri-
genic properties of Cox-2 are part of the reason why
cyclooxygenase inhibitors are under review as a poten-
tial cancer therapy particularly for colon cancer [47].
Previously, Penning et al (1997) established 15 μMt o
be the half maximal inhibitory concentration (IC50) of
celecoxib for Cox-1 and 0.04 μM. In this study, we
chose to examine effects of low celecoxib concentrations
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celecoxib and ensure that most of our observations were
due to Cox-2 inhibition. While the choice of dose did
allow us to observe some Cox-2-dependent effects, we
also found the viability of Cox-2-deficient HCT-116 to
be reduced even at these low concentrations (Figure 4c).
These results are expected considering that other inves-
tigators have demonstrated anti-proliferative effects of
celecoxib to extend beyond Cox-2 inhibition in colon
cancer cell lines [48], hematopoietic and epithelial cell
lines [49] and prostate cancer xenografts [50].
Conclusions
Cox-2-dependent effects of 25-OHC on endothelial cell
proliferation was transient. Prolonged exposure to 25-
OHC caused cell death and enhanced celecoxib-induced
cell death in a less Cox-2 dependent manner. More
importantly, the three EC types represented by the
bovine mesenteric ECs did not respond identically to
the Cox-2 inhibitor celecoxib–bmLECs and bmAECs
but not bmVECs were sensitive to even 5 uM of cele-
coxib (Figures 3 and 4). Thus, Cox-2 inhibitors as anti-
cancer treatments may show cell-type selectivity. Three-
cell models such as our primary cultures of bmLECs,
bmVECs, and bmAECs can aid examination of the effec-
tiveness of celecoxib on proliferation/cell cycle of differ-
ent tumour associated ECs. In future experiments, our
three EC types extracted from bovine mesentery may
also be treated with immune cytokines such as IL-1b
and IL-8, in addition to tumourigenic compounds such
as 25-OHC to recapitulate activated ECs in the colon
tumour environment.
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